ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PRVB Provention Bio Inc

24.98
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Provention Bio Inc NASDAQ:PRVB NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.98 25.04 24.90 0 01:00:00

Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020

30/07/2020 12:00pm

PR Newswire (US)


Provention Bio (NASDAQ:PRVB)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Provention Bio Charts.

OLDWICK, N.J., July 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020.

(PRNewsfoto/Provention Bio, Inc.)

In connection with the earnings release, Provention's management team will host a live conference call and webcast at 8:00 AM ET on Thursday, August 6, 2020, to discuss the Company's financial results and provide a business update.

Conference Call Information
To access the call, please dial 1-888-567-1603 (domestic) or 1-862-298-0702 (international) five minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com.  An archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for seven days following the call. 

About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company leveraging a transformational drug development strategy focused on the prevention or interception of immune-mediated disease. Provention's mission is to source, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune diseases. Provention's diversified portfolio includes teplizumab, a pre-commercial-stage candidate that has been shown to delay the onset of insulin-dependent type 1 diabetes (T1D) in at-risk patients during the presymptomatic phase of the disease. The Company's portfolio includes additional clinical product development candidates that have demonstrated proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Investors:
Sam Martin, Argot Partners
sam@argotpartners.com   
212-600-1902

Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com 
917-553-6808

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-second-quarter-2020-financial-results-and-host-conference-call-on-thursday-august-6-2020-301102826.html

SOURCE Provention Bio, Inc.

Copyright 2020 PR Newswire

1 Year Provention Bio Chart

1 Year Provention Bio Chart

1 Month Provention Bio Chart

1 Month Provention Bio Chart

Your Recent History

Delayed Upgrade Clock